Cytoreductive surgery for advanced ovarian cancer.

about

Role of radical prostatectomy in clinically non-organ-confined prostate cancer.Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer.CT-guided 125I brachytherapy for recurrent ovarian cancer.

P2860

Q38252392-BC19E838-8AAA-4EC0-950F-8F6591D00E81 Q40985469-1F821C30-4F38-413A-90BD-296CE92FF4B3 Q41709694-32EFC81F-EF54-40A8-AE39-06D069883157

P2860

Cytoreductive surgery for advanced ovarian cancer.

Item

http://www.wikidata.org/entity/Q38193876

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cytoreductive surgery for advanced ovarian cancer.

@en

type

Item

label

Cytoreductive surgery for advanced ovarian cancer.

@en

prefLabel

Cytoreductive surgery for advanced ovarian cancer.

@en

P1476

Cytoreductive surgery for advanced ovarian cancer.

@en

P2093

Dennis S Chi

http://www.w3.org/2001/XMLSchema#string

Martin Pölcher

http://www.w3.org/2001/XMLSchema#string

Oliver Zivanovic

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer

Cancer statistics, 2012

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

A phase 3 trial of bevacizumab in ovarian cancer.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.

Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly.

Splenectomy as part of cytoreductive surgery in ovarian cancer.

P304

179-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/WHE.14.4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260607362

http://www.w3.org/2001/XMLSchema#string

P698

24601809

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

Cytoreductive surgery for advanced ovarian cancer.

about

P2860

P2860

Cytoreductive surgery for advanced ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921